Utah Medical Products Inc (UTMD) Stock Price & Analysis
Utah Medical Products Inc (UTMD) rose 1.52% to USD 68.07 as of June 10, 2026 at 03:48 UTC, according to Nexqual real-time market data.
UTMD last closed at USD 67.05; the session ranged USD 66.78–68.78 on volume of 7,980 shares. Market capitalization is $216.74M, with a 52-week range of USD 52–71.81 (NMS). Source: Nexqual, June 10, 2026 at 03:48 UTC.
Key Statistics (as of June 10, 2026 at 03:48 UTC)
| Price | USD 68.07 |
|---|---|
| Change | ▲ 1.52% (up) |
| Previous Close | USD 67.05 |
| Open | USD 66.78 |
| Day Range | USD 66.78 – 68.78 |
| 52-Week Range | USD 52 – 71.81 |
| Volume | 7,980 shares |
| Market Cap | $216.74M |
| Exchange | NMS |
Technical Analysis (UTMD)
Nexqual's technical model rates UTMD "BUY" based on 5 bullish and 1 bearish signals across 124 daily candles, as of June 10, 2026 at 03:48 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 56.56 (neutral) |
| vs SMA50 | Above (USD 65.81) |
| MACD | 0.6 (positive) |
Analyst Ratings (UTMD)
Wall Street analysts rate UTMD "None", per Nexqual as of June 10, 2026 at 03:48 UTC.
| Consensus Rating | None |
|---|
Earnings (UTMD)
| Next Earnings Date | 2026-07-23 |
|---|
Source: Nexqual, June 10, 2026 at 03:48 UTC.
Financials & Fundamentals (UTMD)
| Total Revenue | $37.53M |
|---|---|
| Revenue Growth (YoY) | -10.20% |
| Gross Margin | +57.94% |
| Operating Margin | +34.47% |
| Profit Margin | +28.91% |
| ROE | +9.14% |
| Debt / Equity | 0.17 |
| Current Ratio | 28.64 |
| Total Cash | $87.41M |
| Total Debt | $210,000 |
| Free Cash Flow | $10.04M |
Source: Nexqual, June 10, 2026 at 03:48 UTC.
Financial Health Score (UTMD)
Nexqual rates Utah Medical Products Inc's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 03:48 UTC.
| Growth | Critical — Revenue -10% YoY (latest Q), sharp decline |
|---|---|
| Profitability | Weak — Small revenue base — building scale |
| Balance Sheet | Strong — $87M cash, no debt |
| Cash Flow | Strong — FCF $10M, 25% margin |
| Efficiency | Mixed — ROE 9%, ROA 6.2% |
Ownership (UTMD)
| Insider Ownership | +7.18% |
|---|---|
| Institutional Ownership | +74.93% |
| Shares Outstanding | 3.18M |
| Float | 2.77M |
| Short % of Float | +4.34% |
Source: Nexqual, June 10, 2026 at 03:48 UTC.
Leadership (UTMD)
Utah Medical Products Inc is led by Kevin L. Cornwell (age 78), Chairman, CEO, President & Secretary, per Nexqual as of June 10, 2026 at 03:48 UTC.
| Chairman, CEO, President & Secretary | Kevin L. Cornwell (age 78) |
|---|---|
| Vice President of Marketing | Mark L. Fox |
| Vice President of Corporate Sales | Marcena H. Clawson |
Major Backers & Investors (UTMD)
Notable institutional backers of Utah Medical Products Inc include Brandes Investment Partners L.P., Datum One Series Trust-BRANDES SMALL CAP VALUE FUND, Renaissance Technologies, according to Nexqual as of June 10, 2026 at 03:48 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Brandes Investment Partners L.P. | 14.11% |
| Datum One Series Trust-BRANDES SMALL CAP VALUE FUND | 6.17% |
| Renaissance Technologies | 5.78% |
| Minerva Advisors LLC | 2.94% |
| Hotchkis & Wiley Capital Management, LLC | 2.8% |
| DFA INVESTMENT DIMENSIONS GROUP INC-U.S. Micro Cap Portfolio | 2.7% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 8.59% |
| BlackRock | 8.45% |
| Dimensional Fund Advisors | 6.22% |
| Geode Capital | 3.77% |
Source: Nexqual, June 10, 2026 at 03:48 UTC.
From Utah Medical Products Inc's Latest SEC 10-K Filing (filed 2026-03-27)
Key Strengths & Strategy (as disclosed to the SEC)
- Utah Medical Products, Inc. offers medical devices for the healthcare industry in the United States, Europe, and internationally.
- It offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems.
- The company provides GESCO, an umbilical vessel catheter, including DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATH\NUTRI-LOK feeding device; PICC-NATE, a percutaneous intraepithelial central venous catheter; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies.
- In addition, it offers LETZ system to excise cervical intraepithelial neoplasia and other lower genital tract lesions; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies and gynecologic tools; Femcare trocars, cannulae, laparoscopic instruments, and accessories; and EPITOME and OptiMicro electrosurgical devices.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MLAB | Mesa Laboratories, Inc. | USD 109.03 | ▲ 4.95% |
| USLM | United States Lime & Minerals, | USD 107.45 | ▲ 2.71% |
| WINA | Winmark Corporation | USD 387.62 | ▲ 2.66% |
| CASS | Cass Information Systems, Inc | USD 48.35 | ▲ 1.75% |
| WEYS | Weyco Group, Inc. | USD 35.92 | ▲ 2.39% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:48 UTC. This page is informational and not investment advice.